Following a strategic review, Gerresheimer AG plans to spin off and subsequently sell its Moulded Glass Division with eight plants worldwide. The aim is to focus more strongly on the pharma and biotech business.
Gerresheimer has decided to separate the Moulded Glass business from the corporate structure and subsequently start a sales process. According to the company, the division offers the best growth opportunities as an independent unit. The integration of Bormioli Pharma has created a „Moulded Glass Powerhouse“ with locations in Europe, America and Asia, which generated sales of around EUR 735 million and an Adjusted EBITDA margin of around 20 percent in 2024.
Global production network
The Moulded Glass division comprises eight plants in Germany, Belgium, Italy, the USA and India with around 3,700 employees. It produces type I, II and III glass packaging for the pharmaceutical, cosmetics, food and beverage industries. The portfolio ranges from bottles and containers to jars and flacons. Gerresheimer has invested heavily in modern and energy-efficient production technologies in recent years, including around 100 million euros at the Lohr am Main site.
Next steps and strategic direction
The start of the separation process will lay the foundation for the planned sale, according to the statement. The company intends to present further details at the Capital Market Day on 15 October 2025. The move is part of Gerresheimer's ongoing transformation into a pure systems and solutions provider for the pharma and biotech industry. In addition to primary packaging, the portfolio will increasingly include high-value solutions and integrated plastic systems for biopharmaceutical applications.
Source: Gerresheimer
